Minerva Neurosciences Files Annual Report

Ticker: NERV · Form: ARS · Filed: Apr 23, 2026 · CIK: 0001598646

Sentiment: neutral

Topics: annual-report, sec-filing, pharmaceuticals

TL;DR

Minerva Neurosciences filed its 2025 annual report. Check financials.

AI Summary

Minerva Neurosciences, Inc. filed its Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The company, located at 1500 District Avenue, Burlington, MA, is involved in the pharmaceutical preparations industry. This filing provides a comprehensive overview of the company's performance and financial status for the fiscal year 2025.

Why It Matters

This ARS filing provides shareholders and potential investors with a detailed look at Minerva Neurosciences' financial health and operational performance for the fiscal year 2025, which is crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Minerva Neurosciences is subject to regulatory risks, clinical trial outcomes, and market competition, which can significantly impact its financial performance.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this ARS filing?

The ARS filing serves as the Annual Report to Security Holders, providing a comprehensive overview of Minerva Neurosciences, Inc.'s performance for the period ending December 31, 2025.

When was this Annual Report to Security Holders filed?

This ARS filing was accepted by the SEC on April 23, 2026.

What is the reporting period for this ARS filing?

The period of report for this ARS filing is December 31, 2025.

What is Minerva Neurosciences, Inc.'s business address?

Minerva Neurosciences, Inc.'s business address is 1500 DISTRICT AVENUE BURLINGTON MA 01803.

What is the CIK number for Minerva Neurosciences, Inc.?

The CIK number for Minerva Neurosciences, Inc. is 0001598646.

Filing Details

This Form ARS (Form ARS) was filed with the SEC on April 23, 2026 regarding Minerva Neurosciences, Inc. (NERV).

View full filing on EDGAR

View Full Filing

View this ARS filing on SEC EDGAR

View on Read The Filing